Form 4: C4 Therapeutics Director Utpal Koppikar Acquires Stock Options

Director Utpal Koppikar acquired stock options in C4 Therapeutics, Inc. on June 20, 2024.

Summary

• On June 20, 2024, Utpal Koppikar, a director of C4 Therapeutics, Inc., acquired 32,500 stock options with an exercise price of $4.05.
• These options vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service on the Board.
• Following the transaction, Koppikar directly owns 32,500 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally a positive sign, indicating confidence in the company's future prospects. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service as a member of the Board, aligning the director's interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates